Comparative Pharmacology
Head-to-head clinical analysis: MILPROSA versus SERENTIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MILPROSA versus SERENTIL.
MILPROSA vs SERENTIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Milprosa is a progesterone receptor agonist that induces and maintains endometrial receptivity, inhibits uterine contractions, and suppresses gonadotropin release.
SERENTIL (mesoridazine) is a phenothiazine antipsychotic that blocks postsynaptic dopamine D2 receptors in the mesolimbic system, and also exhibits alpha-adrenergic blocking, anticholinergic, and antihistaminic effects. It has high affinity for D2, 5-HT2A, and alpha-1 receptors.
MILPROSA is not a recognized drug; assuming a typo for milrinone? If milrinone: IV loading dose 50 mcg/kg over 10 minutes, then continuous IV infusion 0.375-0.75 mcg/kg/min.
Oral: 50–100 mg 3 times daily; maximum 400 mg/day. IM: 25 mg every 4–6 hours.
None Documented
None Documented
14 hours (range 10–18); prolonged in renal impairment (up to 40 hours)
Terminal elimination half-life is approximately 24-30 hours in adults. Does not correlate well with duration of antipsychotic effect due to active metabolite formation.
Renal (70% unchanged, 20% as inactive metabolites); fecal (10%)
Primarily renal (70-80% as conjugated and unconjugated metabolites) and fecal (15-20%). Biliary excretion contributes to enterohepatic circulation.
Category C
Category C
Antipsychotic
Antipsychotic